Matrix metalloproteinase-9 (MMP-9) represents one of the most prominent proteins associated with tumorigenesis and is a modulator of the tumor microenvironment during angiogenesis. Recently, syndecan-1 (SDC1), a transmembrane heparan sulfatebearing proteoglycan, was also speculated to have a critical role in contributing to angiogenesis when associated with MMP-9. However, the mechanism behind their synergistic regulation is not fully understood. In the current study, we report for the first time that ionizing radiation (IR)-induced MMP-9 enhances SDC1 shedding, corroborating to tube-inducing ability of medulloblastoma (MB) cells. Furthermore, we observed that the tumor angiogenesis is associated with higher MMP-9-SDC1 interactions on both the cell surface and extracellular medium. Our results also revealed the existence of a novel regulatory mechanism where MMP-9 drives the suppression of miR-494, resulting in enhanced SDC1 shedding and angiogenesis. From the in situ hybridization analysis, we found that MMP-9-specific shRNA (shMMP-9) treatment of mouse intracranial tumors resulted in elevated expression of miR-494. This negative correlation between MMP-9 and miR-494 levels was observed to be dependent on the methylation status of a miR-494 promoter-associated CpG island region ( À 186 to À 20), which was confirmed by bisulfite-sequencing and methylationspecific PCR (MSP) analysis. Further, validation of MMP-9 and SDC1 3 0 -untranslated region (3 0 -UTR) targets with luciferase reporter assay provided a more favorable result for miR-494-mediated regulation of SDC1 but not of MMP-9, suggesting that the 3 0 -UTR of SDC1 mRNA is a direct target of miR-494. Overall, our results indicate that angiogenesis induced by radiotherapy is associated with an MMP-9-miR-494-SDC1 regulatory loop and that MMP-9-SDC1 activity creates a negative feedback loop by regulating the expression of miR-494.
INTRODUCTION
Medulloblastoma (MBs) are primary malignant pediatric brain tumors, with almost 20% recurrence in adulthood. Standard therapies for MB include surgical resection followed by craniospinal radiation therapy 1 or adjuvant chemotherapy. 2 One factor associated with tumor resistance to therapy is increased angiogenesis. 3 Numerous studies demonstrated that radiation-induced angiogenesis in tumor cells can be controlled by inhibiting hypoxia-inducible factor 1 (HIF1), vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), epidermal growth factor receptor (EGFR) and matrix metalloproteinases (MMPs). [3] [4] [5] Despite significant improvements in anti-angiogenesis therapies, tumor vessels continue to express pro-angiogenic factors such as MMP-9, a process termed as 'pro-invasive adaptation mechanism'. 6 Fortunately, targeting MMP-9 has shown to reduce invasion and angiogenesis in different types of cancers. 6, 7 Syndecan-1 (SDC1) also has a role in tumor angiogenesis and invasion when associated with MMP-9. 8, 9 SDC1 is a transmembrane heparan sulfate-bearing proteoglycan that when shed from cell surface promotes tumor growth and angiogenesis. 10, 11 Overexpression of SDC1 showed transcriptional activation of MMP-9 via NF-kappaB. 12 In addition, studies have indicated the role of proteolytically active MMP-9 in SDF-1 and heparanase-induced shedding of SDC1. 13 Molecules that promote shedding of SDC1 are broadly known as sheddases. Cell surfaceassociated sheddase such as Membrane type 1 metalloprotease (MT1-MMP) and soluble sheddase such as MMP-7 were found to induce SDC1 shedding, 14, 15 indicating that SDC1 is a substrate for more than one sheddases. Here, we showed that ionizing radiation (IR)-induced MMP-9 lead to increased SDC1 shedding that promotes MBs tumor angiogenesis. Most interestingly, we observed that transcriptional regulation of both MMP-9 and SDC1 protein involved microRNA-494 (miR-494).
The miRNAs comprise a class of evolutionarily conserved small RNAs (22 nts long) that affect gene expression at the posttranscriptional level by blocking translation or degrading target messenger RNAs (mRNAs). 16, 17 Tissue-specific expression of miR-494 in intestinal-type gastric cancer 18 and its significant role in suppression of cholangiocarcinoma and gastrointestinal stromal tumors 19, 20 indicated the importance of miR-494 as a tumor regulator. The present data suggested the critical role of miR-494 in suppression of tumor angiogenesis-promoting molecules that is translated into increased radiosensitivity in MB cells.
RESULTS

IR induces the expression of angiogenesis-promoting molecules
Previously, we showed that IR treatment induced MMP-9 expression in MB cells. 7 Here, we investigated the effect of IR on upregulation of MMP-9 and other angiogenesis-promoting molecules. Immunoblot analysis of cell membrane (CM) fractions of IR-treated UW228 and D283 cells showed enhanced levels of VEGF-D, Flk-1 (VEGF receptor 2) and pFlk-1 (Po0.001) when compared with control cells (Figure 1a; Supplementary Figure 1a) . In contrast, levels of Timp-1, Timp-2 and SDC1 in CM fractions were decreased (Po0.01) upon IR treatment (Figure 1a ; Supplementary Figure 1a) . Interestingly, the culture filtrate (CF) fractions of IR-treated cells showed increased SDC1 levels (Po0.01) when compared with control cells, indicating shedding of SDC1 (Figure 1b; Supplementary Figure 1b) . This shed SDC1 in CF fraction was lower in molecular mass (B55 kDa) when compared with SDC1 in CM fraction (B84 kDa). Deglycosylation of CF fraction was performed to obtain a discrete band of shed SDC1 (Supplementary Figure 2a) .
Besides shed SDC1, we observed increased MMP-9 and VEGF-D levels among IR-treated CF fractions. Moreover, CF levels of Timp-2 remained low after IR treatment (Figure 1b; Supplementary  Figure 1b) . Earlier, overexpression of a soluble SDC1 form in breast cancer cells was also shown to be associated with reduced Timp-1 expression and increased invasiveness. 21 Further, high levels of shed SDC1 are known to capture VEGF, and this SDC1-VEGF complex promotes endothelial cell invasion during the tumor angiogenesis process. 22 The immunoprecipitation (IP) experiments carried out with CF fractions of control and IRtreated cells using anti-VEGF-D antibody showed increased interaction of SDC1 and VEGF-D in IR-treated cells when compared with control cells, indicating the role of IR in induction of angiogenesis. However, MMP-9 was not detected as a part of this complex (Figure 1c ), thereby indicating a higher Figure 1 . IR treatment induces the expression of angiogenesis-promoting molecules. (a) Immunoblot analysis of CM fraction (40 mg) from control and IR-treated UW228 and D283 cells (an IR dose of 6 Gy was given using the RS 2000 Biological Irradiator X-ray unit (Rad Source Technologies Inc.) and the irradiated cells were further incubated for 24 h). The immunoblots were developed using antibodies specific for Timp-1, Timp-2, VEGF-D, Flk-1, pFlk-1 (Tyr-996) and SDC1; Flotillin was used as loading control. (b) CF fractions were processed using Amicon Ultra-4 (3K) centrifugal filtration units (Millipore) and the concentrated (10-fold) protein fractions were developed using antibodies specific for Timp-2, VEGF-D and SDC1. Gelatin zymography was performed to determine MMP-9 activity in CF fractions as described in Materials and methods. (c) The CF fractions obtained from control and IR-treated UW228 and D283 cells were immunoprecipitated using anti-VEGF-D antibody and immunoblotted against anti-VEGF-D, SDC1 and MMP-9 antibodies. (d) CL fractions (40 mg) were developed using antibodies specific for pERK (Tyr-204) and ERK; GAPDH was used as loading control. (e) Dot-blot assay to measure shed SDC1 levels in CF fraction of UW228 and D283 cells upon addition of increasing concentration of rMMP-9 (10-160 ng). The numbers represent density of each dot, quantitated using Image-Pro Plus software (Media Cybernatics, Inc., Silver spring, MD, USA). (f ) RT-PCR analysis using specific primers for Timp-1, Timp-2, VEGF-D, Flk-1, MMP-9 and SDC1; GAPDH was used as loading control.
affinity of VEGF-D to SDC1. Furthermore, immunoblot analysis of cell lysates (CL) showed increased ERK activation (pERK) (Figure 1d ). Studies reported that activation of ERK upregulates MMP-9, 23 which may apparently act as a sheddase of SDC1. From the dot-blot analysis, we observed that addition of increasing concentrations of human recombinant MMP-9 (rMMP-9) enhanced shedding of SDC1 in CF fractions (Figure 1e ), thus suggesting MMP-9 role in shedding of SDC1. Moreover, RT-PCR analysis also revealed that IR treatment increased the mRNA levels of MMP-9, SDC1, VEGF-D, Flk-1 and decreased Timp-1 and Timp-2 levels (Figure 1f ), similar to the results observed in western blots.
IR-induced MMP-9 increases shedding of SDC1 and promotes endothelial invasion and angiogenesis Having established that IR treatment upregulates MMP-9, we next examined the direct role of IR-induced MMP-9 at promoting angiogenesis and endothelial invasion. Human angiogenesis PCR array in IR-treated cells showed upregulation of several angiogenesis-promoting molecules, which increased further with MMP-9 overexpression. Relative to IR-treated cells, the expression levels of VEGF-D, HIF1a, IFNB1, ID3 and TNF were significantly upregulated in MMP-9 overexpressing (MMP-9OE) þ IR-treated cells by at least twofold. However, the expression level of Timp-1 was downregulated in MMP-9OE þ IR-treated cells and showed significant increase upon shRNA for MMP-9 (shMMP-9) þ IR treatment (Figure 2a; Supplementary Table 2 ). The immunoblot analysis demonstrated that shMMP-9 treatment suppressed VEGF-D and shed SDC1 levels in CF fraction, whereas IR treatment and addition of exogenous rMMP-9 to shMMP-9-treated cells restored VEGF-D and SDC1 shedding (Po0.001) (Figure 2b ; Supplementary  Figure 1c) . However, we found that IR accompanied with rMMP-9 treatments showed a robust increase in shed SDC1 and VEGF-D levels ( Figure 2b Figure 2c) . Alternatively, treatment with shMMP-9 showed inhibition of angiogenesis network formation (Figures 2c and d) . We also validated our results using additional siRNA specific for MMP-9 (siMMP-9) from a commercial source (Santa Cruz Biotechnology, Santa Cruz, CA, USA). Both siMMP-9 and siMMP-9 þ IR treatments showed reduced mRNA expression levels of MMP-9 when compared with control and IR-treated UW228 and D283 cells (Supplementary Figure 3a) . Furthermore, downregulation of MMP-9 using siMMP-9 decreased shedding of SDC1 in CF fractions and suppressed the angiogenesis tube-inducing ability of UW228 and D283 cells (Supplementary Figures 3b and c) .
Next, we investigated whether IR-induced upregulation of MMP-9 had any paracrine role on human endothelial cells (HMEC). The CF fractions of control and IR-treated cells were passed through a 50-kDa cutoff Amicon ultra-filters that retained MMP-9 protein and rejected the shed form of SDC1 (Figure 2e ). MMP-9 containing fraction was then diluted in serum-free media (1:10) and overlaid onto HMEC. We observed that HMEC treated with MMP-9 containing CF fractions of cancer cells showed increased SDC1 shedding (Po0.01) when compared with untreated HMEC control cells. This shedding of SDC1 by HMEC was further enhanced when treated with CF fractions of IR-treated MB cells (Figure 2e ). Moreover, RT-PCR analysis of HMEC showed lower endogenous levels of MMP-9 and MMP-9 overexpression in these cells showed increased SDC1 mRNA levels, which enhanced further upon IR treatment (Supplementary Figure 4a) . Alternatively, addition of increasing concentrations of rMMP-9 to HMEC also resulted in increased SDC1 shedding, which was quantified using SDC1 ELISA kit (Supplementary Figure 4b) . MMP-9 protein functionally and physically interacts with both cellassociated and shed SDC1 To confirm the involvement of MMP-9 in mediating SDC1 shedding, we measured the accumulation of shed SDC1 in CF fractions of IR-treated cells, both in the presence and in the absence of an antibody (MMP-9-PEX-Ab) specific for MMP-9 hemopexin domain, which blocks MMP-9 activity. This MMP-9-PEX-Ab (10 mg/ml) significantly blocked shedding of SDC1 (Po0.001) and showed increased accumulation of SDC1 in CM fraction of IR-treated MB cells (Figure 3a; Supplementary  Figure 1d ). To study if the MMP-9 and SDC1 interaction is essential for SDC1 shedding, we performed IP using CF and CM fractions of control and IR-treated D283 cells and human MB tumor tissue extracts. We observed that MMP-9 physically interacts with both cell-associated and shed SDC1 (Supplementary Figure 4c) . The MB tumor tissue extracts also showed increased MMP-9-SDC1 interactions when compared with human normal brain (NB) tissue extract. However, we observed differential expression of MMP-9-SDC1 in different tumor tissue extracts (Figure 3b ). Consistent with these results, colocalization studies performed on MB tumor tissue array (US Biomax, Rockville, MD, USA) also confirmed this interaction (Figures 3c and d) .
High serum levels of shed SDC1 are correlated with poor prognosis in cancer patients. 24 Hence, we quantified the levels of shed SDC1 in serum samples of nude mice that were intracranially implanted with D283 control or MMP-9 overexpressing (MMP-9OE) stable cells alone and in combination with shMMP-9 and IR treatments. SDC1 ELISA kit used to quantify shed SDC1 in serum samples of treated mice showed significant increase in shed SDC1 with MMP-9OE and IR treatments, whereas shMMP-9 treatment showed decreased levels of shed SDC1 (Figure 3e ). Immunofluorescence staining of the respective in vivo tumor sections of treated mice also showed increased MMP-9-SDC1 colocalization with MMP-9OE and IR treatments, which was suppressed upon shMMP-9 treatment (Figures 3f and g; Supplementary Figure 5 ). These findings indicate that MMP-9 overexpression in tumor cells contributes substantially to SDC1 shedding by their colocalization at the invasive front.
3
0 -Untranslated regions of MMP-9 and SDC1 mRNA contain conserved target sites for miR-494 Using miRanda 25 and PITA 26 algorithms, we found that both MMP-9 and SDC1 were the potential targets of miR-494 ( Figure 4a ). The miR-494 binding, 6-mer and 7-mer motifs in 3 0 -untranslated region (3 0 -UTR) of MMP-9 and SDC1 respectively were found to be highly conserved in multiple mammalian species The CF fractions obtained from control and treated UW228 and D283 cells were subjected to immunoblot analysis using specific antibodies for VEGF-D and SDC1. MMP-9 activity was determined by gelatin zymography. (c) Quantitative analysis of tube-forming ability of HMEC upon treatment with CF fractions of UW228 and D283 cells transfected with pSV and shMMP-9 plasmids alone or in combination with rMMP-9 (100 mM) or IR treatment. The percent of branch points times branches was calculated and represented graphically. (d) Cranial window experiment in nude mice to show the angiogenesis tube-forming ability of D283 control, MMP-9 overexpressing (MMP-9OE) stable cells with or without shMMP-9 and IR treatments. The microscopic examination of cranial window using stereo zoom dissection microscope (SZX12, Olympus, Melville, NY, USA) at a Â 60 magnification. The mice were intravenously administered with shMMP-9 plasmid on Day 3 and Day 5 of cancer cell spheroid implantation (see Supplementary data for details). The vascular length density was calculated in treated and control animals by dividing the total vessel length in a frame by the area of the frame. (e) The CF fractions obtained from UW228 and D283 cells were concentrated using Amicon ultra-4 centrifugal filters of molecular weight cutoff 50 kDa. The concentrated high molecular mass CF fraction was examined for MMP-9 and shed SDC1 levels by gelatin zymography and immunoblot analysis, respectively. The HMEC were then treated overnight with high molecular mass CF fraction (1:10 times diluted). The CF fractions obtained from untreated control and treated (UW228-CF and D283-CF) HMEC were processed and immunoblotted against anti-SDC1 antibody. CF represents culture filtrate and SFM represents serum-free media.
MMP-9, miR-494 and SDC1 in tumor angiogenesis S Asuthkar et al decrease in luciferase expression, with an approximate 80% decrease in luciferase activity when treated with 50 pmol of miR-494 mimic (Figure 5b ). In contrast, the increasing concentrations of miR-494 showed no significant change in the pISO/MMP-9UTR reporter luciferase activity (data not shown). These data indicated specificity of miR-494 towards cognate mRNA-3 0 UTR sequence of SDC1. Further, miR-494 inhibitor (Inh), co-transfected together with 50 pmol of miR-494 mimic and pISO/SDC1UTR reporter construct showed increased reporter gene activity in a dosedependent manner (Figure 5b , inlet graph). Co-transfection with 150 pmol of miR-494 Inh almost restored the miR-494-mediated luciferase gene repression of pISO/SDC1UTR (Figure 5c ). Further, analysis of CF fractions of UW228 and D283 cells treated with miR-494 mimic showed decreased levels of shed SDC1 and MMP-9 proteins (Po0.01) in both control and IR-treated cells (Figure 5d ; Supplementary Figure 1e) . Interestingly, the cell-associated SDC1 was also suppressed by 45% in miR-494-treated cells, indicating inhibition of total levels of SDC1 (Figure 5d) . Alternatively, addition of miR-494 Inh to above miR-494-treated cells completely restored the expression of SDC1 and increased the levels of active MMP-9 ( Figure 5d) .
Interestingly, when compared with IR treatment, miR-494 overexpression in MB cells showed reduced ERK activation along with inhibition of total SDC1 levels ( Figure 5d ). Since, SDC1 was shown to serve as a co-receptor for receptor tyrosine kinases and to assist in growth factor (bFGF)-mediated proliferation of Figure 3 . MMP-9 protein physically interacts with SDC1 to facilitate tumor growth. (a) The IR-treated UW228 and D283 cells were treated with MMP-9-PEX-Ab (10 mg/ml), which blocks the hemopexin domain of MMP-9, and incubated further for 24 h. The CM and CF fractions were subjected to immunoblot analysis using anti-SDC1 antibody; Flotillin was used as loading control for CM fraction. (b) IP of MB tumor (#1 to #5) and NB tissue extracts was performed using anti-MMP-9 antibody and the immunoprecipitates were immunoblotted against anti-SDC1 and MMP-9 antibodies. (c) MB brain tissue microarray (US Biomax), containing 20 cases (60 cores), was processed for immunohistochemistry using Alexa fluor anti-SDC1 (green) and anti-MMP-9 (red) secondary antibodies as described in Materials and methods. cells, 21, 27 we investigated the co-receptor role of SDC1 in MB cells. We first examined the bFGF-2 levels in the CF of IR-treated cells. Next, the activation of ERK in SDC1 downregulated control and irradiated cells was also assessed. We observed that IR-treated cells released significantly high levels of bFGF-2 into CF, suggesting that FGF has a role to play in IR-induced proliferation of these cells (Figure 5e ). Moreover, IR-induced activation of ERK was markedly reduced in SDC1 downregulated cells, thereby representing a role for SDC1 in FGF-2 signaling in these cells (Figure 5f; Supplementary Figure 6c (Figures 6a and b) , thus indicating the negative role of miR-494 in MB tumor progression and angiogenesis.
To further investigate the negative regulation of miR-494 in MB cells, we considered an alternative mechanism of miRNA downregulation by epigenetic transcriptional silencing. 28 We investigated whether MMP-9 expression was associated with altered DNA methylation of miR-494 promoter in MB cells. We established the DNA methylation status of nine CpG sites at known or predicted transcriptional start sites of pri-miRNA-494 promoter in primary MB tumors and in a panel of seven MB cell lines by bisulphite sequencing. Figure 6c (top) shows a schematic representation of CpG island and corresponding regions of bisulfite sequencing-specific PCR (BSP) and methylation-specific PCR (MSP) primers, designed using MethPrimer software. 29 The bisulphite-modified DNA was amplified using BSP primers and sequenced. The methylation statuses of nine CpG sites within the CpG island of miR-494 promoter region ( À 186 to À 20) are shown in Figure 6c (down) , and the representative sequences obtained by bisulfite sequencing are shown in Supplementary  Figure 6d . From our results, we concluded that the amplified where R max and R min are the maximum and minimum tumor radii, respectively (mean ± s.d., n ¼ 5; *, Po0.05).
MMP-9, miR-494 and SDC1 in tumor angiogenesis S Asuthkar et al miR-494 promoter region was densely methylated in MB tumor cells (78% of samples tested). In contrast, this region of miR-494 promoter was demethylated in human normal brain (NB) tissues (60% of samples tested) and shMMP-9-treated MB cells (72% of the samples tested), indicating MMP-9 role in transcriptional silencing of miR-494 expression.
In view of the findings published in various articles, 22, 23, 30 we hypothesized the existence of a link between histone acetyltransferase (HAT) activity and increased MMP-9 transcription in IR-treated MB cells. To explore this, we added increasing concentrations of anacardic acid, a potent inhibitor of HAT 31 to IR-treated MB cells and incubated for another 4 h. The addition of HAT inhibitor (30 mM) significantly quenched the expression levels of MMP-9 mRNA in IR-treated cells (Figure 6d) . Further, the decrease in MMP-9 expression among IR þ HAT inhibitor-treated cells was significantly high when compared with both HAT inhibitor-treated control and HAT inhibitor-untreated control and IR cells (Figure 6e ). Analogous patterns of MMP-9 activity in CF and MMP-9 protein expression in cell extracts were observed from gelatin zymograms and western blots, respectively (Figure 6e ). All these data suggested that increased MMP-9 expression among IR-treated cells could be related to HAT activity. Interestingly, we also observed a decline in DNMT1 mRNA levels in HAT inhibitor-treated MB cells (Figure 6e ; Supplementary  Figure 1f ) in accordance with the earlier report that HAT activity regulates DNMT1 expression in mouse somatic cells. 32 MMP-9-specific methylation-dependent transcriptional silencing of miR-494 promoter and re-expression of miR-494 following demethylating treatment Two MSP primer sets were designed to amplify either methylated (M) or unmethylated (U) bisulfite-modified sequence in miR-494 promoter (Figure 7a ). Representative results of human NB and MB tissues are shown in Figure 7b . In MB tissues, which showed aberrantly high expression of MMP-9 ( Supplementary Figure 6e) , prominent PCR products were visible in methylated lane representing methylation at the promoter CpG regions of miR-494. However, in NB samples, PCR products were obtained specifically for unmethylated primer set indicating no methylation The CF fractions were processed using Amicon Ultra-4 (3K) centrifugal filtration units (Millipore) and the concentrated (10-fold) proteins were developed using anti-SDC1 antibody. MMP-9 activity was determined by gelatin zymography. The CL fraction proteins were developed using antibodies specific for SDC1, pERK (Tyr-204) and HIF1a; GAPDH was used as loading control. (e) Immunoblot analysis of FGF-2 in equal volumes of CF fractions from control and IR-treated UW228 and D283 cells. HMW, high molecular weight; LMW, low molecular weight; FGF-2, fibroblast growth factor-2. (f ) SDC1 modulates FGF-2-mediated ERK signaling in IR-treated MB cells; CL (40 mg) from control and treated-(IR and siRNA for SDC1 (siSDC1)) UW228 and D283 cells were developed using antibodies specific for pERK and ERK.
at CpG regions of miR-494 (Figure 7b) . Furthermore, to determine whether silencing of miR-494 by MMP-9 levels was associated with a change in methylation pattern of miR-494 promoter, four MMP-9 overexpressing cell lines (UW228, D283, D425 and H2402) (Supplementary Figure 6f) were used for MSP analysis. The cells were then subjected to shMMP-9 and IR treatments and the genomic DNA isolated was amplified using MSP primers. Interestingly, only the cells knocked down for MMP-9 showed PCR products in unmethylated lane, indicating no methylation of miR-494 promoter CpG islands. However, control, MMP-9OE and IR-treated cells showed prominent PCR products with methylated primer (Figure 7c ). These results confirm dense methylation of miR-494 promoter in MB cells and further that shMMP-9 treatment induces demethylation of miR-494 promoter, which leads to transcriptional activation of miR-494. This finding is consistent with our ISH analysis (Figure 4c) . Further, we treated the cells with active demethylating agent, 5-Aza-CdR, as described in Materials and methods in combination with MMP-9 overexpression. Treatment of MB cells with 5-Aza-CdR resulted in visible PCR products in unmethylated lane, representing hypomethylation at promoter CpG regions of miR-494. In contrast, in PBS-treated or MMP-9 overexpressing cells, prominent PCR products remained specific for methylated CpG islands as observed in methylated lane (Figure 7d) . Furthermore, from the miR-quantitative real-time PCR analysis we observed that miR-494 expression was significantly upregulated (Po0.01) following 5-Aza-CdR treatment, thus showing evidence of methylation-dependent transcriptional silencing. Interestingly, MMP-9 overexpression in these cells inhibited 5-AzaCdR-dependent de-silencing of miR-494 (Figure 7e ). We next investigated the levels of DNMT1 mRNA in shMMP-9, siMMP-9 and RT-PCR analysis was also done using specific primers for MMP-9, DNMT1 and DNMT3A; GAPDH was used as loading control.
siSDC1 as well as in MMP-9OE cells. The shMMP-9-treated cells showed diminished levels of DNMT1 mRNA; on the other hand, MMP-9OE cells showed elevated expression of DNMT1. Nonetheless, siSDC1 showed a decrease in DNMT1 mRNA expression to a lesser extent (Figure 7f ). These results further revealed a strong regulatory role of MMP-9 over SDC1 on the promoter methylation of miR-494.
DISCUSSION
Increasing evidence suggests that localization of proteolytically active MMP-9 at the cell surface is a key event in promoting tumor invasion and angiogenesis. 33 Recently, studies mentioned the possible role of MMP-9 in mediating SDC1 core protein cleavage near the CM. 22 Shedding of SDC1 ectodomain from cells can be induced by a direct proteolytic cleavage, by a variety of cellular stress conditions and by activation of several other intracellular signaling pathways that converge to activate a cell-surface metalloproteinase(s) (MMPs). 34, 35 In our studies, we observed that both MMP-9 overexpression and MMP-9 downregulation in IR-treated cells showed significant modulation in shedding of SDC1, indicating that the expression of angiogenic factor SDC1 depends very strongly on MMP-9 levels in MB cells. Further, the angiogenesis process involves interactions between various extracellular matrix (ECM) proteins in which MMP-9-PEX domain has a key role in terms of proteolytic activity and substrate binding. 36 In our study, we showed that blocking of the MMP-9-PEX domain failed to induce SDC1 shedding. Since angiogenesis involves complex interconnected components, a network approach would be a convenient systemic way for directed drug attacks. Here, we show the existence of a potentially important functional relationship between MMP-9 and SDC1 with miR-494 in tumor growth and angiogenesis.
MiRNAs have recently emerged as salient regulators of cancer processes and are considered as valuable for possible in vivo therapeutics. 37 We observed that upregulation of miR-494 is associated with reduced MB tumor growth and angiogenesis. Out of 7 and 32 miRs targeting MMP-9 and SDC1 respectively, only miR-494 was predicted to commonly target both of the oncoproteins. Further, validation of MMP-9 and SDC1-3 0 UTR targets with luciferase reporter assay provided a more favorable result for miR-494-mediated regulation of SDC1 but not of MMP-9, suggesting that the conserved 7-mer AUGUUUC region within the 3 0 -UTR of SDC1 was responsible for miR-494 targeting. A recent study on breast cancer cells revealed a conserved SDC1-3 0 UTR (ACAGGGU) region as a functionally relevant target of the oncomiR miR-10b. Interestingly, depletion of SDC1 in breast cancer cells also showed downregulation of MMP-9. 9 However, our immunoblot results showed consistent reduction in both MMP-9 and SDC1 protein levels in miR-494-treated MB cells, indicating the negative regulation of these proteins. Furthermore, we found that miR-494 also targets other angiogenesis-promoting molecules such as HIF1a (Figure 5d; Supplementary Figure 6b ). All these data shed further light on the anti-angiogenic ability of miR-494 through the targeting of angiogenesis-promoting molecules.
Studies showed that miRNA expression profiles differ between normal tissues and derived tumors. 38 Moreover, miRNAs with tumor suppressor features in human cancer, such as miR-203, are epigenetically silenced by CpG island promoter-associated methylation. 39 Interestingly, we found that CpG island region ( À 186 to À 20) associated with miR-494 promoter was densely methylated in MB primary tumors and cell lines. In contrast, shMMP-9-treated MB cells showed a demethylation similar to that of NB samples. Aberrant promoter-associated CpG methylation of tumor-suppressor genes is a major epigenetic event in human cancers including MB 40 and appears to be mediated by MMP-9 in this case. The high expression levels of MMPs in primary gastric cancer tissues inhibited the secreted frizzled-related proteins, primarily due to hypermethylation of SFRP5 promoter. 41 Further, DNA methylation is brought about by a group of enzymes known as DNMTs. 42 The DNMT1 and DNMT3b are known to control the transcription of miR-148a, miR-34b/c, miR-9 and let-7 by gene promoter methylation. 43 Interestingly, a large body of data demonstrates that DNMT activity is elevated in neoplastic cells and is associated with increased tumorigenesis. 44 Apart from DNA methylation by DNMTs, the histone acetylation/deacetylation is also profoundly altered in human cancers. The literature suggests that this epigenetic cross-talk may be involved in gene transcription and aberrant gene silencing. 45, 46 We observed decreased MMP-9 and DNMT1 mRNA levels in HAT inhibitor-treated MB cells. Also, evidence from other studies suggest the activation of NF-kB in HAT-induced MMP-9 expression 47 and binding of the Sp1/NF-kB complex to the DNMT1 promoter. 48 A recent study on DNMT1 downregulation has shown a negative effect on arsenite-induced MMP-9 expression revealing a direct association between DNMT1 and MMP-9. 49 All of these studies and our observations indicate a possible regulatory loop mechanism between HAT, MMP-9 and DNMT1 that could regulate the expression of miR-494 (Figure 8) . Future study will be needed to elucidate the possible roles of DNMT family members in MB de novo tissue-specific gene methylation.
Our studies show that the molecular mechanisms underlying methylation-mediated silencing of miR-494 in MB cells are presumably, due in part, to the MMP-9 expression levels. However, its exact molecular mechanism needs to be further studied.
In summary, we showed that miR-494 expression is silenced in MB cells and that angiogenesis induced by radiotherapy is associated with an MMP-9-miR-494-SDC1 regulatory loop. In view of these findings, targeting components of this regulatory loop have significant therapeutic implications through the regulation of tumor growth and angiogenesis.
MATERIALS AND METHODS
Ethics statement
The Institutional Animal Care and Use Committee of the University of Illinois College of Medicine at Peoria, Peoria, IL, approved all surgical interventions and post-operative animal care (protocol #857, dated 27 May 2009 and renewed on 30 June 2012). Human MB primary tumor tissues were obtained from patients (Age: 2-16 years) undergoing therapeutic surgery at the Children's Hospital, OSF Saint Francis Medical Center (Peoria, IL). NB tissue samples were obtained from patient biopsies due to other conditions. All sample diagnoses (as tumor tissues or NB tissue) and staging were confirmed by a pathologist. Human MB of brain tissue microarray was purchased from US Biomax (see Supplementary data and Supplementary Table 3 ).
Cell lines, transfection and IR
The MB cell line D283 Med (HTB-185) was obtained from American Type Culture Collection (ATCC) and authenticated by DNA profile, using the Figure 8 . Diagrammatic representation of radiation-induced upregulation of angiogenesis-promoting molecules and that the balance between miR-494 and MMP-9-SDC1 axis determines the angiogenic ability of MB cells. We report that IR-induced MMP-9 enhances SDC1 shedding and tube-inducing ability of MB cells. Furthermore, shed SDC1 via ERK activation controls MMP-9 expression, indicating positive feedback loop mechanism between MMP-9 and SDC1. Tumors are known to actively protect themselves from radiation damage by promoting endothelial cell radioresistance. One such study has shown that radiotherapy-induced HIF1 expression is a crucial step in radioprotection of tumor vasculature. 3 Similary, in MB cells, we observed that radiation treatment enhances the expression of several angiogenesis-promoting molecules including MMP-9, SDC1 and HIF1a, which are shown to be the potential targets of miR-494 in the present study. However, we do believe that HIF1a is the upstream molecule in angiogenesis signaling and studies have shown that activation of HIF1a transactivates hundreds of genes including MMPs. 59 In this study, we showed that downregulation of MMP-9 (shMMP-9) when compared with IR treatment has a potential therapeutic implication that may shift the balance toward miR-494 regulating the MMP-9-SDC1 axis during tumor angiogenesis. In view of the various findings published in various articles, 22, 23, 30, 49 we also hypothesized that there could be a positive regulatory link between HAT, MMP-9 and DNMT1 that could regulate the expression of miR-494. TF, transcription factor.
short tandem repeat, cytogenetic analysis and isoenzymes. D425, D341, D458, H2402 and H2405 cells were kindly provided by Dr Darell D Bigner (Duke University Medical Center); UW228 cells were kindly provided by Dr Ali-Osman (Duke University Medical Center). These cells were authenticated on the basis of c-Myc amplification and chromosomal aberrations by the provider 50, 51 and were cultured following standard protocols. 52 HMEC were cultured according to standard protocol. 53 All transfection experiments were performed with FuGene HD transfection reagent (Roche, Indianapolis, IN, USA) (see Supplementary data). For combination treatments, an IR dose of 6 Gy was given after 48 h of transfection using the RS 2000 Biological Irradiator X-ray unit (Rad Source Technologies Inc., Boca Raton, FL, USA). Irradiated cells were further incubated for 24 h. MMP-9-shRNA and overexpression constructs, miRNA, antago-miRNA, antibodies and reagents
The shRNA specific for MMP-9 (shMMP-9) and MMP-9 overexpression construct were generated in our laboratory 7 and a pCDNA3-scrambled vector (pSV) with an imperfect sequence was used as control. The hsa-miR-494 mimic and hsa-miR-494 inhibitor (Inh) were purchased from Qiagen (Germantown, MD, USA) and Exiqon (Woburn, MA, USA) respectively. The antibodies were purchased from Santa Cruz Biotechnology. Human rMMP-9 (pro and active) was purchased from Millipore (Temecula, CA, USA). Cells were grown in the presence of 5 mM demethylating agent 5 0 -Aza-2 0 -deoxycytidine (5-Aza-CdR) (Sigma, St Louis, MO, USA) for 3 days, following standard protocol. 54 Anacardic acid (HAT inhibitor) was purchased from Sigma. The CM and CL were prepared as described previously. 7 CF fractions were first concentrated by 10-fold using Amicon Ultra-4 (3K) centrifugal filters (Millipore, Billerica, MA, USA). Western blot, gelatinase zymography and IP assays were carried out according to previously established protocol. 55 Reverse-transcription PCR RT-PCRs were performed according to standard protocol using specific primers listed in Supplementary Table 1. Mir-quantitative real-time PCR Total RNA was isolated using TRIZOL reagent (Invitrogen, Carlsbad, CA, USA). For miRNA analysis, 100 ng of template RNA was reverse transcribed using universal cDNA synthesis kit (Exiqon) and miR-494-specific RT primers (Exiqon) following supplied protocol. MiR-494 transcript levels were examined by real-time PCR using CFX96 Real Time System (Bio-Rad, Hercules, CA, USA).
Bisulfite modification of genomic DNA, bisulfite-sequencing and MSP Genomic DNA was isolated from MB primary tumors and cells using DNeasy tissue kit (Qiagen). Bisulfite reaction was carried out on 5 mg of genomic DNA using EpiTect bisulfite kit (Qiagen) following supplied protocol. Bisulfite modified DNA (200 Zg) was amplified by BSP and MSP primers (see Supplementary data).
In vitro and in vivo (Cranial window method) angiogenesis assay Tumor cell-induced microtubule network formation was determined as described previously. 56 An open cranial window was implanted in nude mice by following Levassuer et al., 57 protocol (see Supplementary data).
The vascular length density was calculated by dividing the total vessel length in a frame by the area of the frame. 58 Surgical orthotopic implantation D283 control and MMP-9 overexpressing (MMP-9OE) stable cells (1 Â 10 6 ) with or without IR treatment were injected intracerebrally into nude mice following standard protocol. 7 ISH, immuno-cyto and histochemistry
The ISH was done using miRCURY LNA microRNA ISH Optimization Kit and full-length miR-494 hybridization probe (Exiqon) following supplied protocol (see Supplementary data).
Statistical analysis
For statistically significant data analysis, please see Supplementary data and Supplementary Figure 1 .
